Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Применение трансдермальных лекарственных форм нестероидных противовоспалительных препаратов у пациентов с поясничной болью
Умарова Х.Я., Камчатнов П.Р. Применение трансдермальных лекарственных форм нестероидных противовоспалительных препаратов у пациентов с поясничной болью. Consilium Medicum. 2014; 16 (9): 85–89.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Mafi J, McCarthy E, Davis R, Landon B. Worsening Trends in the Management and Treatment of Back Pain. JAMA Intern Med 2013; 2. doi:10.1001/jamainternmed.2013.8992.
2. Carnes D, Homer K, Underwood M et al. Pain management for chronic musculoskeletal conditions: the development of an evidence-based and theory-informed pain self-management course. BMJ Open 2013; 3: e003534. doi:10.1136/bmjopen-2013-003534.
3. Kennedy A, Reeves D, Bower P. The effectiveness and cost effectiveness of a national lay-led self care support programme for patients with long-term conditions: a pragmatic randomised controlled trial. J Epidemiol Community Health 2007; 61: 254–61.
4. Garcia-Rodriguez L, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12: 570–6.
5. Schaffer D, Florin T, Eagle C et al. Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review MJA 2006; 185 (9): 501–6.
6. Есин Р.Г., Есин О.Р., Ахмадеева Г.Д., Салихова Г.В. Боль в спине. Казань: Казанский полиграфкомбинат, 2010.
7. Каратеев А.Е., Насонова В.А. НПВП-ассоциированная гепатопатия. Научно-практическая ревматология. 2003;
4: 87–91.
8. McGettigan P, Henry D. Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income Countries. PLoS Med 2013; 10 (2): e1001388. doi:10.1371/ journal. pmed.1001388.
9. Fosbol E, Folke F, Jacobsen S et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010; 3 (4): 395–405.
10. Kohli P, Steg P, Cannon C. NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease. Am J Med 2014; 127 (1): 53–60.
11. Bavry A, Khaliq A, Gong Y, Handberg E. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. Am
J Med 2011; 124 (7): 614–20.
12. Grosser T, Fries S, FitzGerald G. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4–15.
13. Brattwall M, Turan I, Jakobsson J. Musculoskeletal pain: prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004–2008 – a retrospective patient record review. J Pain Res 2010; 3: 131–5.
14. Batysheva TT, Otcheskaya OV, Kamchatnov PR et al. Efficacy of the Combination of Arthrosan and Combilipen in Patients with Acute Lower Spinal Pain. Neurosci and Behavioral Physiology 2013; 43 (2): 240–3.
15. Scott N, Moga C, Harstall C. Managing low back pain in the primary care setting: The know-do gap. Pain Res Manage 2010; 15 (6): 392–400.
16. Smeets L, Moore R, Edwards J et al. Topical NSAIDs for acute pain: a meta-analysis. BMC Fam Pract 2004; 5: 10–6.
17. Камчатнов П.Р., Чугунов А.В., Трубецкая Е.А. Пациент с болью в спине: возможности терапии. Нервно-мышечные болезни. 2013; 2: 20–7.
18. Spofford C, Ashmawi H, Subieta A et al. Ketoprofen produces modality-specific inhibition of pain behaviors in rats after plantar incision. Anesth Analg 2009; 109 (6): 1992–9.
19. Mason L, Moore R, Edwards J et al. Topical NSAIDs for acute pain: a meta-analysis. BMC Fam Pract 2004; 5: 10–6.
20. Montastier P. Etude de la cinétique de diffusion in vitro de quatre AINS destinés à la voie percutanée. Médicine du sport 1994; 68 (1): 40–4.
21. Mazieres B. Topical ketoprofen patch. Drugs R D 2005; 6: 337–44.
22. Gürol Z, Hekimoğlu S, Demirdamar R, Sumnu M. Percutaneous absorption of ketoprofen. I. In vitro release and percutaneous absorption of ketoprofen from different ointment bases. Pharm Acta Helv 1996; 71 (3): 205–12.
2. Carnes D, Homer K, Underwood M et al. Pain management for chronic musculoskeletal conditions: the development of an evidence-based and theory-informed pain self-management course. BMJ Open 2013; 3: e003534. doi:10.1136/bmjopen-2013-003534.
3. Kennedy A, Reeves D, Bower P. The effectiveness and cost effectiveness of a national lay-led self care support programme for patients with long-term conditions: a pragmatic randomised controlled trial. J Epidemiol Community Health 2007; 61: 254–61.
4. Garcia-Rodriguez L, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12: 570–6.
5. Schaffer D, Florin T, Eagle C et al. Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review MJA 2006; 185 (9): 501–6.
6. Есин Р.Г., Есин О.Р., Ахмадеева Г.Д., Салихова Г.В. Боль в спине. Казань: Казанский полиграфкомбинат, 2010.
7. Каратеев А.Е., Насонова В.А. НПВП-ассоциированная гепатопатия. Научно-практическая ревматология. 2003;
4: 87–91.
8. McGettigan P, Henry D. Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income Countries. PLoS Med 2013; 10 (2): e1001388. doi:10.1371/ journal. pmed.1001388.
9. Fosbol E, Folke F, Jacobsen S et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010; 3 (4): 395–405.
10. Kohli P, Steg P, Cannon C. NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease. Am J Med 2014; 127 (1): 53–60.
11. Bavry A, Khaliq A, Gong Y, Handberg E. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. Am
J Med 2011; 124 (7): 614–20.
12. Grosser T, Fries S, FitzGerald G. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4–15.
13. Brattwall M, Turan I, Jakobsson J. Musculoskeletal pain: prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004–2008 – a retrospective patient record review. J Pain Res 2010; 3: 131–5.
14. Batysheva TT, Otcheskaya OV, Kamchatnov PR et al. Efficacy of the Combination of Arthrosan and Combilipen in Patients with Acute Lower Spinal Pain. Neurosci and Behavioral Physiology 2013; 43 (2): 240–3.
15. Scott N, Moga C, Harstall C. Managing low back pain in the primary care setting: The know-do gap. Pain Res Manage 2010; 15 (6): 392–400.
16. Smeets L, Moore R, Edwards J et al. Topical NSAIDs for acute pain: a meta-analysis. BMC Fam Pract 2004; 5: 10–6.
17. Камчатнов П.Р., Чугунов А.В., Трубецкая Е.А. Пациент с болью в спине: возможности терапии. Нервно-мышечные болезни. 2013; 2: 20–7.
18. Spofford C, Ashmawi H, Subieta A et al. Ketoprofen produces modality-specific inhibition of pain behaviors in rats after plantar incision. Anesth Analg 2009; 109 (6): 1992–9.
19. Mason L, Moore R, Edwards J et al. Topical NSAIDs for acute pain: a meta-analysis. BMC Fam Pract 2004; 5: 10–6.
20. Montastier P. Etude de la cinétique de diffusion in vitro de quatre AINS destinés à la voie percutanée. Médicine du sport 1994; 68 (1): 40–4.
21. Mazieres B. Topical ketoprofen patch. Drugs R D 2005; 6: 337–44.
22. Gürol Z, Hekimoğlu S, Demirdamar R, Sumnu M. Percutaneous absorption of ketoprofen. I. In vitro release and percutaneous absorption of ketoprofen from different ointment bases. Pharm Acta Helv 1996; 71 (3): 205–12.
Авторы
Х.Я.Умарова1, П.Р.Камчатнов2
1. ФГБОУ ВПО ЧГУ, Грозный;
2. ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва
1. ФГБОУ ВПО ЧГУ, Грозный;
2. ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.